Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL
Abstract Background A novel treatment has been developed for erythropoietic protoporphyria (EPP) (a rare condition that leaves patients highly sensitive to light). To fully understand the burden of EPP and the benefit of treatment, a novel patient reported outcome (PRO) measure was developed called...
Saved in:
Main Authors: | G. Biolcatti (Author), S. Hanneken (Author), E. I. Minder (Author), N. J. Neumann (Author), J. H. P. Wilson (Author), P. J. Wolgen (Author), D. J. Wright (Author), A. J. Lloyd (Author) |
---|---|
Format: | Book |
Published: |
SpringerOpen,
2021-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction to: Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL
by: G. Biolcati, et al.
Published: (2021) -
Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice
by: Jasmin Barman-Aksözen, et al.
Published: (2017) -
Acquired erythropoietic protoporphyria secondary to myelodysplastic syndrome: from mythology to oncologyAcquired Erythropoietic Protoporphyria Secondary to Myelodysplastic Syndrome: From Mythology to Oncology
by: Mirjana Urosevic-Maiwald, et al.
Published: (2024) -
Erythropoietic Protoporphyria in a Japanese Population
by: Megumi Mizawa, et al.
Published: (2019) -
Illuminating Dersimelagon: A Novel Agent in the Treatment of Erythropoietic Protoporphyria and X-Linked Protoporphyria
by: Katelyn E. Madigan, et al.
Published: (2023)